Arcturus Therapeutics (NASDAQ:ARCT) Price Target Cut to $25.00 by Analysts at Piper Sandler

Arcturus Therapeutics (NASDAQ:ARCT) had its price objective decreased by Piper Sandler from $72.00 to $25.00 in a research note issued to investors on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock.

Several other brokerages have also issued reports on ARCT. Wall Street Zen lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Roth Mkm initiated coverage on Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. HC Wainwright dropped their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Finally, Citigroup cut their price objective on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

Arcturus Therapeutics Stock Down 4.2%

Shares of NASDAQ ARCT opened at $7.58 on Wednesday. Arcturus Therapeutics has a 12 month low of $5.85 and a 12 month high of $24.17. The business’s 50 day moving average is $7.29 and its two-hundred day moving average is $11.35. The company has a market cap of $215.35 million, a P/E ratio of -3.18 and a beta of 2.40.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.11). The company had revenue of $7.20 million during the quarter, compared to the consensus estimate of $14.32 million. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 28.63%. Sell-side analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its position in shares of Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after buying an additional 738,378 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Arcturus Therapeutics by 1,371.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock worth $10,177,000 after buying an additional 514,652 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Arcturus Therapeutics during the 1st quarter worth about $4,892,000. Bank of America Corp DE raised its stake in Arcturus Therapeutics by 112.0% in the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after buying an additional 327,626 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Arcturus Therapeutics by 170.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company’s stock valued at $2,398,000 after acquiring an additional 246,499 shares during the period. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics News Roundup

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Pipeline progress: Arcturus outlined the launch of a 12‑week Phase II cystic fibrosis (CF) trial and said it expects regulatory clarity for ARCT‑810 in 2026 — a near‑term catalyst if milestones and timelines hold. Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026 Q4 and FY2025 results and pipeline progress
• Neutral Sentiment: Minor analyst tweak: Citigroup raised its price target from $7 to $8 but kept a “neutral” rating — a modest endorsement but not a strong near‑term buy signal. Citigroup raises ARCT price target to $8
• Neutral Sentiment: Reported short‑interest data in recent summaries appears erroneous (zero shares / NaN change) and is not a meaningful indicator of current positioning. No reliable short‑squeeze signal is evident from those entries.
• Negative Sentiment: Quarterly miss: ARCT reported Q4 EPS of ($1.03) vs. consensus ($0.92) and revenue of $7.2M vs. $14.32M expected — the revenue shortfall and wider loss are the main drivers of the pullback. ARCT reports Q4 loss, misses revenue estimates Market reaction and Q4 details
• Negative Sentiment: Analyst volatility: Piper Sandler cut its price target sharply from $72 to $25 (still “overweight”), increasing headline risk and uncertainty around valuation — a big downward revision that can weigh on sentiment despite the maintained rating. Piper Sandler lowers ARCT PT to $25
• Negative Sentiment: Market reaction: Coverage noted an immediate share drop after the weak revenue print; higher‑than‑average intraday volume suggests selling pressure as investors digest the miss. ARCT falls on weak quarterly revenue

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.